Study of Everolimus in Chinese Patients with Advanced Solid Tumors
Author Information
Author(s): Xu BingHe, Wu YiLong, Shen Lin, Ye DingWei, Jappe Annette, Cherfi Azzeddine, Wang Hui, Yuan RuiRong
Primary Institution: Cancer Hospital Chinese Academy of Medical Sciences
Hypothesis
Everolimus will be safe and effective in Chinese patients with advanced solid tumors.
Conclusion
Everolimus 5 or 10 mg/day was well tolerated in Chinese patients with advanced solid tumors.
Supporting Evidence
- Everolimus was absorbed rapidly with median Tmax of 3 hours for 5 mg and 2 hours for 10 mg.
- The most common adverse events were increased blood glucose and fatigue.
- Best tumor response was stable disease in 83% of patients on 5 mg and 50% on 10 mg.
Takeaway
This study tested a medicine called everolimus in Chinese patients with serious cancers to see if it was safe and worked well.
Methodology
24 patients were randomized to receive either 5 mg or 10 mg of everolimus daily, and their safety and pharmacokinetics were assessed.
Limitations
The study had a small sample size and was limited to specific cancer types.
Participant Demographics
Patients included 12 with breast cancer, 6 with gastric cancer, 6 with non-small cell lung cancer, and 6 with renal cell carcinoma.
Statistical Information
Confidence Interval
95% CI for stable disease duration was 2.89-8.05 months for 5 mg/day and 3.58-not reached for 10 mg/day.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website